For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ TB-500
Illustration for TB-500

THE PEPSRADAR ENCYCLOPEDIA

TB-500

Thymosin-fragment research

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Corrected October 11, 2026: We removed upcoming-trial records that turned out not to be real studies (fake ClinicalTrials.gov registrations). Corrections log

TB-500 · KEY FACTS

Content updated · how dates work

Saved peptides

Compare: BPC-157 vs TB-500

What is TB-500?

TB-500 is associated with a short thymosin beta-4 fragment. Much of the biology cited in marketing instead concerns the full-length parent peptide.

Video overview · 3:30

TB-500: What the Research Actually Shows (and Why It Isn't Thymosin Beta-4)

How TB-500 differs from the natural protein thymosin beta-4, what the rat and cell studies found, why the only human trials tested the full protein, and its safety, FDA and anti-doping status.

Narrated with an AI voice from this profile's sources; education only, no dosing.

Read the transcript

TB-500 is a lab-made peptide sold online and linked to a natural protein called thymosin beta-4. It is promoted for injury recovery, but it is not an approved medicine, and no published study has tested it in people. Here is what is actually known.

Thymosin beta-4 is a natural protein of forty-three amino acids, found in almost every cell. TB-500 is different. Anti-doping labs that analyzed it found one short stretch, seven amino acids long, with an added chemical group. And a French racing lab found products sold as TB-500 did not consistently match their descriptions.

Thymosin beta-4 is the main molecule cells use to hold actin, a building block of the cell skeleton, in reserve. In a 2003 lab study, its seven amino acid actin-binding stretch helped blood-vessel cells migrate, about as well as the whole protein. That is a lab hypothesis, not proof of what happens in an injured person.

Much of the repair research used the full protein: in rats, thymosin beta-4 helped skin wounds close faster. Studies of TB-500 itself are few. In a 2024 cell study, the intact peptide did not significantly speed healing, though one of its breakdown products did. A 2026 rat study linked TB-500 to stronger repaired Achilles tendons. These are early, lab-stage findings.

In people, there are no published studies of TB-500, and the FDA says it has not identified any human exposure data. No one knows how the body handles it, what side effects it may cause, or whether it helps.

Human trials have tested only the full protein, mostly as eye drops called RGN-259. In nine people with severe dry eye, the drops eased discomfort and surface damage, but a trial of seventy-two people missed both main goals. In a hard-to-heal corneal condition, six of ten treated patients healed, versus one of eight on placebo, just short of statistical significance.

Small, short trials of the full protein found side effects infrequent and mild to moderate, but that says little about TB-500. The FDA warns it may carry a risk of immune reactions, and in 2026 FDA staff advised against allowing it in pharmacy compounding. The agency has also warned a seller that its TB-500 was an unapproved drug. It is not FDA approved, and the World Anti-Doping Agency bans it in sport.

Is TB-500 the same as thymosin beta-4? PepsRadar's claim check says not supported: labs found a seven amino acid fragment, not the full forty-three amino acid protein. Do the eye-drop trials show TB-500 works? No, they tested the full protein. And is BPC-157 with TB-500 a proven combination? No human trial has tested it, and in one rat study the pair did no better than either alone.

The bottom line: TB-500 is not thymosin beta-4, it has never been tested in a published human study, and what is in a vial is uncertain. For every study and source, see the TB-500 profile on PepsRadar dot com.

Biological role or research focus

Thymosin-fragment research.

FDA identifies a thymosin beta-4 fragment under this name. Findings about full-length thymosin beta-4 do not automatically transfer.

Role reference: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗

Names you may encounter

TB 500 · TB500 · thymosin beta-4 fragment

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Thymosin beta-4-related fragment
Main research area
Identity and repair-mechanism research
Evidence featured
Related-peptide mechanistic review
Source check
October 4, 2026

Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗

Quick answers

Is TB-500 FDA approved?
No. No FDA-approved drug contains TB-500. Source ↗
Is TB-500 safe?
Unapproved fragment of thymosin beta-4. FDA found no human exposure data and flagged immune-reaction and impurity risks; its safety in people is unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
Is TB-500 banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.3 Growth factors and growth factor modulators). Source ↗
Has the FDA taken action over TB-500?
Yes. Our records list 3 FDA actions naming it, most recently on October 28, 2026: HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

2 Related compound / review
StudyTypePopulation / model
Thymosin beta-4 active regions (2010)Related-peptide mechanistic reviewPublished experimental work on full-length thymosin beta-4 and shorter sequences.
RGN-259 in severe dry eye — related molecule (2015)Related-compound human trialNine patients with severe dry eye; 12 treated eyes and six control eyes.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Related-peptide mechanistic review · 2010

Thymosin beta-4 active regions

Biological activities of thymosin beta4 defined by active sites in short peptide sequences.

Population / model
Published experimental work on full-length thymosin beta-4 and shorter sequences.
Study design
Structure/function synthesis discussing different active regions; not a human clinical trial.
Main finding
The paper discusses migration and wound-related activity associated with a sequence containing LKKTETQ, alongside other active regions of the parent protein.
Limits & context
This is background on related sequences, not direct clinical evidence for a marketed TB-500 preparation. It must not be presented as a human recovery trial.

Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗

Related-compound human trial · 2015

RGN-259 in severe dry eye — related molecule

What does a small full-length thymosin β4 eye-drop study actually tell us?

Population / model
Nine patients with severe dry eye; 12 treated eyes and six control eyes.
Study design
Randomized, double-masked, vehicle-controlled phase 2 trial with follow-up to day 56.
Main finding
The abstract reported improvements in ocular discomfort and corneal staining at selected assessments, including day 56, with the thymosin β4 formulation.
How to read it
The participants are nine people, not 18 independent people. The studied preparation was RGN-259 eye drops containing full-length thymosin β4.
Limits & context
A very small trial with multiple assessments. It does not test a TB-500 fragment, systemic administration, tendon repair, or a seller’s vial. Related-compound evidence must not be presented as a TB-500 clinical trial.

Source: G Sosne and colleagues · Cornea · 2015 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming TB-500 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Search additional PubMed records ↗

Risks & interactions

Unapproved fragment of thymosin beta-4. FDA found no human exposure data and flagged immune-reaction and impurity risks; its safety in people is unknown.

Human safety data: None

No published human safety studies of TB-500 were found, and FDA says it identified no human exposure data. Small studies of full-length thymosin beta-4 do not establish the fragment's safety.

Unassessed: no human safety data

Warning signs in animal or lab studies: Cancer, now or in the past

It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Serious risks

  • Possible immune reactions (immunogenicity) and peptide impurities, per FDA's compounding safety listing

Harms seen in animal or lab studies

  • In tumor and lab studies, higher levels of the parent protein thymosin beta-4 have been linked to tumor spread and blood-vessel growth

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks ↗ · Biological activities of thymosin beta4 active sites (2010) ↗ · Thymosin beta4: a potential molecular target for tumor therapy (review) ↗

Safety evidence & remaining uncertainty

FDA identifies a human-exposure data gap. Evidence about a parent protein cannot establish fragment or commercial-preparation safety.

Source: FDA · Peptide compounding safety concerns ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. FDA presented TB-500 (free base and acetate) to its Pharmacy Compounding Advisory Committee on July 23, 2026, proposing that it NOT be added to the 503A bulks list. On October 28, 2026, HHS filed an interim enforcement discretion policy covering TB-500 (Federal Register 2026-22192): HHS does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding it while rulemaking proceeds. That is not listing on the 503A bulks list and not FDA approval. source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S2.3 Growth factors and growth factor modulators
Named explicitly ("Thymosin-beta4 and its derivatives e.g. TB-500"). source

FDA actions

  • HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). TB-500 is one of six peptides in its Appendix A (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500). HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with these peptides while FDA develops the 503A bulks list by rulemaking. It is not an FDA approval, does not add TB-500 to the 503A bulks list, is not binding, and HHS may revisit it if a safety signal or quality problem arises. The comment period on regulations.gov closed on November 13, 2026 (docket HHS-OASH-2026-0496). (2026-10-28) source
  • FDA presented TB-500 (free base and acetate) to its Pharmacy Compounding Advisory Committee (July 23, 2026) for possible addition to the 503A bulks list; FDA's briefing document proposed NOT adding it. The committee's vote is advisory; no final FDA decision found. (2026-07) source
  • FDA warning letter (Warrior Labz) citing TB-500 and BPC-157 products sold online as unapproved new drugs. (2023-06-12) source

Other notes

  • Australia, November 5, 2026: TGA laboratory testing of one brand's unapproved peptide products, identified while assisting NSW Police (Strike Force Antree), found no detectable TB-500 in three products labelled as containing it, and "Retatrutide 10 mg" vials with less retatrutide than stated, with significant variation between samples. The TGA says consumers cannot rely on the labels to know what they are taking or how much. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & status

The linked mechanistic paper is related background, not a clinical TB-500 efficacy trial. FDA identifies the LKKTETQ fragment under this name. Exact sequence and modification must be checked before associating a study with a listing.

Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Mechanism & research rationale

Thymosin beta-4 research examines actin-related processes, cell migration, and wound responses. Different regions can have different activities; a short sequence does not inherit all parent-protein effects.

Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗

Molecular structure

TB-500: 2d molecular structure. The acetylated seven-residue fragment Ac-LKKTETQ is shown, not full-length thymosin beta-4.⤢ Enlarge 2D
2D molecular structureThe acetylated seven-residue fragment Ac-LKKTETQ is shown, not full-length thymosin beta-4.PubChem · CID 62707662 ↗

Questions worth asking

  • What specific product, route, and research population does the claim refer to?
  • Does the source measure an outcome in people, or only a laboratory marker?
  • FDA identifies a thymosin beta-4 fragment under this name. Findings about full-length thymosin beta-4 do not automatically transfer.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Is full-length thymosin beta-4 the same as TB-500 fragment?

No. This distinction can determine whether the entire cited evidence is relevant.

Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗

Is there a direct human recovery trial on this page?

No. The selected publication is mechanistic background and is labeled accordingly; it should not be read as proof of clinical recovery.

Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗

What does the RGN-259 in severe dry eye — related molecule study show, and what does it not?

The participants are nine people, not 18 independent people. The studied preparation was RGN-259 eye drops containing full-length thymosin β4. A very small trial with multiple assessments. It does not test a TB-500 fragment, systemic administration, tendon repair, or a seller’s vial. Related-compound evidence must not be presented as a TB-500 clinical trial.

Source: G Sosne and colleagues · Cornea · 2015 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

PUT THE EVIDENCE IN CONTEXT

Research guides

RESEARCH FIELD GUIDE

Where research peptides come from, and why the batch matters more than the brand

Dozens of online shops sell research peptides, and many look like different companies selling the same products. We compared 15 shops' menus, prices and 98 of their lab reports. The pattern fits a market where many brands buy finished vials from a few manufacturers and sell them under their own labels. So the question to ask isn't "which brand?" but "was the lot I'm buying tested, and does the lab confirm it?"

Read the guide →

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

TB-500

Download illustration ↓Source record ↗
TB-500 2d molecular structure

The acetylated seven-residue fragment Ac-LKKTETQ is shown, not full-length thymosin beta-4.